Quantcast
Last updated on April 23, 2014 at 11:02 EDT

Latest drug discovery Stories

2014-04-23 08:32:54

Resource Will Provide Comprehensive Overview of the Science for Prevention Therapies NEW YORK, April 23, 2014 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) announced today the launch of Cognitive Vitality, a new online resource developed to provide a comprehensive and credible overview and analysis of the science for specific strategies to prevent Alzheimer's and related dementias. The resource showcases the strength of the science for and against...

2014-04-23 08:31:22

The Department of Defense's WRAIR will study Lpath's anti-LPA antibody in the blast injury model of TBI SAN DIEGO, April 23, 2014 /PRNewswire/ -- Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, and scientists from the Center for Military Psychiatry and Neuroscience, Walter Reed Army Institute of Research (WRAIR), have initiated a study that is the focus of a collaborative research agreement. The collaboration involves the use of...

2014-04-23 08:31:14

CHARLOTTESVILLE, Va., April 23, 2014 /PRNewswire/ -- HemoShear, LLC, the human disease biology company, today announced research collaboration with Medivir AB of Stockholm, Sweden, an emerging research-based pharmaceutical company focused on infectious diseases. The collaboration will explore the application of HemoShear's platform in an undisclosed area of strategic interest. In this initial phase of the collaboration, HemoShear will characterize biological mechanisms and the effects...

2014-04-22 08:32:58

- Potential Therapeutic Candidates Now Identified for All Three GSK Collaboration Targets - CAMBRIDGE, Mass., April 22, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the achievement of the lead candidate milestone for the third of the three histone methyltransferase (HMT) targets in the company's collaboration with GSK and is...

2014-04-18 23:04:53

Live webinar to focus on using quantitative phosphoproteomics to support the discovery and development of kinase-selective drugs. The broadcast takes place on Wednesday, May 7, 2014 at 10:00am EDT (15:00 UK BST/ GMT +1). Toronto, Canada (PRWEB) April 18, 2014 The study of phosphoproteomics represents a major leap forward in drug target and mode of action analysis: Deregulated protein kinase signaling occurs in many human diseases such as cancer, inflammatory disorders or neurodegenerative...

2014-04-18 23:04:04

Panel at DIA Annual Meeting to Explore Leveraging Data and Analytics to Enhance Collaboration Washington (PRWEB) April 18, 2014 The impact of “big data” on the partnerships between contract research organizations (CROs) and clinical trial sponsors will be discussed at the DIA 2014 50th Annual Meeting, June 15 to 19, in San Diego. The “Big Data, Big Impact: New Levels of Strategic Partnerships Between Sponsors-CROs” forum, held on June 17 at 8 a.m. in the San Diego Convention...

2014-04-17 16:26:44

SHERBROOKE, Quebec and BIRMINGHAM, Ala., April 17, 2014 /PRNewswire-USNewswire/ -- Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the research and development of novel drug candidates based on proprietary macrocyclic chemistry, today announced the signing of a discovery and co-development agreement with Southern Research Institute, a not-for-profit 501(c)(3) scientific research organization founded in 1941. The collaboration will utilize Cyclenium's...

2014-04-17 00:21:10

DUBLIN, April 17, 2014 /PRNewswire/ -- Heart Metabolics Limited, a new Irish biotechnology company focused on development of drugs for cardio-metabolic diseases, has announced the completion of a $20 million Series A financing from venBio, Seroba Kernel Life Sciences, Brandon Capital Partners (on behalf of AustralianSuper) and AshHill. The proceeds from this financing have supported Heart Metabolics Limited in acquiring a Phase 3-ready drug candidate and related preclinical drug...

2014-04-16 23:10:31

High Throughput Screening (HTS) Market is expected to witness a high growth in the label-free technology segment, as this technology offers direct detection. http://www.marketsandmarkets.com/Market-Reports/high-throughput-screening-market-134981950.html (PRWEB) April 16, 2014 According to the new market research report the “High Throughput Screening (HTS) Market by Technology (Cell Based, Ultra High Throughput Screening (UHTS), Label Free, Bioinformatics), by Applications (Target...

2014-04-16 23:04:11

The industry will grow strongly as testing of new drugs continues. For this reason, industry research firm IBISWorld has added a report on the Contract Pharmaceutical Research Services industry to its growing industry report collection. New York, NY (PRWEB) April 16, 2014 The industry provides a breadth of research and development (R&D) services to manufacturers in the pharmaceutical industries. In the past five years, brand-name drug producers have faced increasing threats from...